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Abstract
Purpose: The purpose of this study is to investigate the dosimetric characteristics of volumetric modulated arc
therapy (VMAT) with flattening filter-free (FFF) beams and assess the role of VMAT in the treatment of advanced
nasopharyngeal carcinoma (NPC).
Methods: Ten cases of CT data were randomly selected from advanced NPC patients. Three treatment plans were
optimized for each patient, RapidArc with FFF beams (RA-FFF), conventional beams (RA) and static gantry
intensity-modulated radiation therapy (IMRT). The doses to the planning target volumes (PTVs), organs at risk (OARs),
skin and normal tissue were compared. All the plans were delivered on a Varian TrueBeam linear accelerator and
verified using the Delta4 phantom. Technical delivery parameters including the mean gamma score, treatment
delivery time and monitor units (MUs) were also analyzed.
Results: All the techniques delivered adequate doses to the PTVs. RA-FFF gave the highest D1% (dose received by 1%
of the volume), but the poorest conformity index (CI) and homogeneity index (HI) among the PTVs except for the
planning target volume of involved regional lymph nodes (PTV66) CI, which showed no significant difference among
three techniques. For the planning target volume of the primary nasopharyngeal tumor (PTV70), RA-FFF provided for
higher mean dose than other techniques. For the planning target volume receiving 60 Gy (PTV60) and PTV66, RA
delivered the lowest mean doses whereas IMRT delivered the highest mean doses. IMRT demonstrated the highest
percentage of target coverage and D99% for PTV60. RA-FFF provided for the highest doses to the brain stem, skin and
oral cavity. RA gave the highest D1% to the right optic nerve among three techniques while no significant differences
were found between each other. IMRT delivered the highest mean doses to the parotid glands and larynx while RA
delivered the lowest mean doses. Gamma analysis showed an excellent agreement for all the techniques at 3%/3mm.
Significant differences in the MUs were observed among the three techniques (p< 0.001). Delivery times for RA-FFF
and RA were 152 ± 7s and 153 ± 7s, respectively, nearly 70% lower than the 493 ± 24smean time for IMRT.
Conclusions: All treatment plans met the planning objectives. The dose measurements also showed good
agreement with computed doses. RapidArc technique can treat patients with advanced NPC effectively, with good
target coverage and sparing of critical structures. RA has a greater dosimetric superiority than RA-FFF.
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Introduction
Radiotherapy treatment for nasopharyngeal carcinoma
(NPC) is often difficult due to the location of several
tumor-adjacent organs at risk (OARs) including the brain
stem, spinal cord, parotid glands and optic nerves. The
application of sophisticated techniques is required to
minimize the risk of toxicity or to adequately deliver
curative doses. RapidArc is based on the volumetric mod-
ulated arc therapy (VMAT) technique and is developed to
simultaneously optimize the multi-leaf collimator (MLC)
shape, dose rate and gantry angle. It can obtain a dose dis-
tribution similar to the static gantry intensity-modulated
radiation therapy (IMRT). Numerous studies have pre-
viously compared the dose distribution of VMAT and
IMRT, and generally suggested that VMAT provides rapid,
safe and accurate radiotherapy for many tumors, such as
lung, gliomas, brain metastases, and some head and neck
cancers [1-5].
TrueBeam (Varian Medical Systems, Palo Alto, CA)
is a new linear accelerator designed to deliver flat-
tened, as well as flattening filter-free (FFF) beams. The
bremsstrahlung distribution from photons in the MeV
energy range is strongly forward peaked and demonstrates
both an energy and intensity variation of the primary
photon fluence with emission angle. To compensate for
this variation, the flattening filter has been introduced
in the treatment head of a medical accelerator, which
results in an almost uniform dose at a certain depth. With
the development of IMRT techniques in all its forms,
the flattening filter in many cases becomes redundant
because the MLC can be used to reach the desired dose
distribution.
There is an increasingly interest in the clinical usage of
FFF beams. It was found that RapidArc with FFF beams
results in minor improvements in plan quality with the
potential for additional useful reduction in the treatment
time for advanced esophageal cancer [6]. Subramaniam
et al. [7] also reported that for chest wall radiotherappy,
RapidArc with FFF beams showed the possibility to fur-
ther reduce the dose delivered to healthy tissue compared
to RapidArc with conventional flattened beams, suggest-
ing their applicability for large and complex targets. With
FFF beams the dose rate is increased up to 1400 monitor
unit (MU)/min for the 6MV beam. The removal of flat-
tening filter was also shown to reduce of out-of-field dose
due to the reduction of head scatter and residual electron
contamination. This leads to a possible faster treatment
with reduced out-of-field dose exposure [8,9]. The main
purpose of the present study is to assess the role of FFF
beams in reducing the doses to the OARs while preserving
adequate target coverage. It has been previously demon-
strated that for medium and small size targets, FFF beams
might be suitable for IMRT planning and that the out-
of-field dose could be significantly reduced, resulting in
better OAR protection [10]. It is important to demonstrate
whether these advantages could be extended to large tar-
gets in a complex anatomic situation such as NPC. The
second objective is to determine whether VMAT can be
effective in the treatment of advanced NPC, confirming
the data obtained by other groups [11-13].
Materials andmethods
Patient characteristics
This study included 10 advanced NPC patients (median
age 53 years, range 33–76 years) who had received radio-
therapy continuously in the Radiation Oncology Depart-
ment, Tumor Hospital of Shantou University Medical
College. According to the stage of NPC (American Joint
Committee on Cancer’s staging system 7th), the clinical
stages of patients were as follows: stage III, 6 and stage
IV, 4. Among these 10 patients, two patients had been
diagnosed as T4 and two patients as N3.
Delineation of target volumes and OARs
All target volumes were delineated slice by slice on the
treatment planning CT images according to the Interna-
tional Commission on Radiation Units andMeasurements
Report 83 guidelines [14]. Gross tumor volume (GTV)
was defined as the gross extent of the tumor shown by
CT/MRI imaging, and this included the primary nasopha-
ryngeal tumor (GTV70) as well as all involved regional
lymph nodes (GTV66). Clinical target volume (CTV) was
defined as the GTV plus a 5–10 mm margin for potential
microscopic spread, including the regional lymph node
draining areas. Planning target volumes (PTVs), which
include PTV70, PTV66 and PTV60, were generated by
3mm outer margin of GTV70, GTV66 and CTV, respec-
tively. The PTV66 and PTV60 were also generated by
3 mm apart from the surface of the body to avoid the
parts extended to the outside of the body and the build-
up effect. The median volumes for PTV70, PTV66 and
PTV60 were 51± 27cm3, 66± 33cm3, and 537± 137cm3,
respectively. The lengths of the targets for all patients
were >20cm. The OARs, including the spinal cord, brain
stem, lens, optic nerves, parotid glands, oral cavity and
larynx, were contoured following anatomic definitions.
Normal tissue was defined as the body volume sub-
tracted by all the PTVs and OARs, and the skin was
defined as the ring generated by the 7mm inter margin of
the body.
Treatment plan management
Three treatment plans were optimized for each patient
on the CT imaging, RapidArc with FFF beams (RA-
FFF), RapidArc with conventional flattened beams (RA)
and static gantry IMRT. The IMRT plans were gen-
erated using sliding window dynamic delivery with
conventional beams.
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All RapidArc plans and IMRT plans were optimized on
the Eclipse treatment planning system (Varian Medical
Systems, Palo Alto, CA), using 6MV or 6MV FFF beams
from a TrueBeam linear accelerator (Varian Medical Sys-
tems, Palo Alto, CA). Considering the large target volumes
of advanced NPC and surrounding complex OARs, two
arcs were adopted for both RapidArc plans and the copla-
nar fixed 9-field plan, seperated at 40° apart, was selected
for IMRT. For RapidArc, the collimator rotation was set
at 30° and two coplanar arcs were delivered with opposite
rotation (clockwise and anticlockwise). The maximal dose
rate was set to 600 monitor units (MU)/min for RA and
1400 MU/min for RA-FFF. For IMRT, a fixed dose rate of
600 MU/min was applied and the collimator rotation was
set at 0°.
The accelerator was calibrated to deliver 0.01Gy/MU to
water at a depth of maximal dose for a 10×10cm field at a
source-to-surface distance of 100 cm following the Amer-
ican Association of Physicists in Medicine Task Group
51 report [15]. Optimization methods and parameters
were similar for all patients across all three techniques.
The progressive resolution optimizer algorithm (version
10.0.28) was used for RapidArc optimization and the dose
volume optimizer algorithm (version 10.0.28) for IMRT.
The planning objectives for the target volumes and OARs
used in this study are listed in Table 1. For all patients,
the dose volume constraints were defined to match the
planning objectives and the normal tissue objective auto-
matic tool was activated to minimize the dose spread
outside the PTVs. Volumetric doses were calculated using
the anisotropic analytical algorithm (version 10.0.28) with
a dose calculation grid of 2mm. The simultaneous boost
Table 1 The planning objectives in both RapidArc and
IMRT plans for NPC
Structures Planning objectives
PTV70 V70 ≥ 95%,D1% ≤ 77Gy
PTV66 V66 ≥ 95%
PTV60 V60 ≥ 95 %
Brain stem D1% < 60Gy
Spinal cord D1% < 45Gy
Optic nerves D1% < 50Gy
Lens D1% < 10Gy
Larynx Dmean < 40Gy
Oral cavity Dmean < 40Gy
Parotid glands Dmean < 40Gy
Normal tissue as low as possible
Abbreviations: PTV70 = planning target volume of the primary nasopharyngeal
tumor; PTV66 = planning target volume of involved regional lymph nodes;
PTV60 = planning target volume receiving 60 Gy; VD = the percentage volume
of the PTV at the prescribed dose and D was the prescribed dose; D1% = dose
received by 1% of the volume.
plan was used and the prescribed doses were 70 Gy to
PTV70, 66 Gy to PTV66 and 60 Gy to PTV60 in 31
fractions. Each plan was normalized to meet the same
objectives with 70 Gy covering 95% of the PTV70.
Quantitative evaluation of the plans was performed
using the mean of dose-volume histograms (DVHs). For
the PTVs, D99% and D1% (dose received by 99% and 1% of
the volume), mean dose, target coverage (VD), conformity
index (CI), and homogeneity index (HI) were compared.
VD was the percentage volume of the PTV at the pre-
scribed dose and D was the prescribed dose. CI was
calculated using the equation: CI = (PTVref ÷ VPTV ) ×
(PTVref ÷ Vref ), where PTVref represented the volume
receiving the prescription dose in the target volume,VPTV
stood for the volume of the PTV, and Vref was the volume
that received the prescribed dose. HI was evaluated as the
difference between D1% and D99% divided by the prescrip-
tion dose [16-18]. For OARs, D1% was applied to evaluate
the doses to the brain stem, spinal cord, optic nerves,
and lens, and the mean dose was applied to evaluate the
doses to parotid glands, larynx, oral cavity, normal tissue
and skin. The treatment delivery time (including machine
preparation) and the MUs of the three techniques were
also compared. The RapidArc and IMRT fields were con-
nected to each other as doable with TrueBeam.
Dose verification
Phantom dose verifications were also performed for all
the plans using the Delta4 (ScandiDos, Uppsala, Sweden).
It is a cylindrical phantom for patient specific quality
assurance. Absorbed dose was measured in two orthog-
onal detector arrays. The spacing between detectors is
5 mm in the center (8 × 8cm2) and 10 mm outside
(20 × 20cm2). The measured dose planes were compared
to the ones computed with a criterion of 3% and 3mm.
A detector point was considered to pass if the calcu-
lated gamma index (GI) was smaller than 1. Points with
less than 10% of the maximum dose were not taken
into account.
Statistical analysis
SPSS 11.0 software (IBM, Chicago, IL) was applied
for statistical data management and analysis. To deter-
mine statistical significance, the non-parametric Fried-
man and post hoc Wilcoxon tests were performed
with p-values < 0.05 considered to be significant.
The data were presented as the averages over all
patients and error was the one standard deviation
level.
Results
All 10 cases in the study received RA-FFF treatment plan-
ning, with a prescribed dose of 70Gy to 95% of the PTV70,
resulting in a mean PTV70 dose of 72.80 ± 0.72Gy.
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Corresponding RA and IMRT treatment planning
resulted in a mean PTV70 dose of 72.15 ± 0.68Gy,
71.95 ± 0.21Gy, respectively. The dose distributions
for the three plans are shown for 1 patient in Figure 1.
Figure 2 presents the average DVHs for the PTVs and
OARs for the entire group of patients.
Table 2 lists the statistical data of the PTVs for all stud-
ied cases. All techniques met the planning requirement
for delivering the prescribed dose to at least 95% of the
PTVs, and IMRT demonstrated the highest percentage
of target coverage (p = 0.002) and D99% (p = 0.006) for
PTV60. RA-FFF provided for higher D1% than other tech-
niques and gave the poorest CI and HI for the PTVs
except for the CI for PTV66, which showed no signifi-
cant difference among the three techniques. For PTV70,
RA-FFF also provided for higher mean dose than other
techniques (p = 0.007). For PTV60 and PTV66, RA
delivered the lowest mean doses, which were closer to
the prescribed doses, whereas IMRT delivered the high-
est mean doses. No significant difference among the
different techniques could be established in other PTV
parameters.
There was no significant difference in D1% delivered to
the spinal cord, lens and left optic nerve (Table 3). Each
technique also provided similar mean dose to normal tis-
sue of patients included in this study. RA-FFF provided
for higher D1% to the brain stem (p = 0.014) and higher
mean doses to the oral cavity (p = 0.025) and skin (p =
0.008) compared to other techniques. RA gave the high-
est D1% to the right optic nerve among three techniques
(p = 0.007) while no significant differences were found




Figure 1 The dose distributions for three techniques.







Figure 2 Dose-volume histograms for three techniques.
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Table 2 Comparison of PTV doses among the three techniques
Target RA-FFF RA IMRT p value p1 p2 p3
PTV70
D99%(Gy) 68.52± 0.46 68.69± 0.59 69.06± 0.22 0.122 — — —
D1%(Gy) 75.40± 1.32 74.08± 1.12 74.30± 0.62 0.007 0.005 0.028 0.878
Dmean(Gy) 72.80± 0.72 72.15± 0.68 71.95± 0.21 0.007 0.005 0.012 0.333
V70(%) 95.00± 0.00 95.00± 0.00 95.00± 0.00 — — — —
CI 0.486± 0.213 0.609± 0.199 0.519± 0.220 0.014 0.007 0.445 0.037
HI 0.087± 0.023 0.067± 0.021 0.069± 0.011 0.008 0.005 0.028 0.646
PTV66
D99%(Gy) 65.26± 0.99 65.19± 0.98 66.07± 1.09 0.121 — — —
D1%(Gy) 72.74± 1.58 71.34± 1.46 72.25± 1.53 0.008 0.008 0.314 0.799
Dmean(Gy) 69.67± 0.99 68.90± 0.85 70.18± 1.18 0.001 0.008 0.155 0.008
V66(%) 97.65± 1.28 97.53± 1.37 99.08± 0.60 0.050 — — —
CI 0.209± 0.074 0.244± 0.074 0.226± 0.083 0.169 — — —
HI 0.108± 0.054 0.088± 0.052 0.080± 0.048 0.001 0.008 0.008 0.123
PTV60
D99%(Gy) 57.97± 0.84 57.88± 0.77 58.54± 0.71 0.006 0.508 0.009 0.009
D1%(Gy) 74.31± 1.08 73.38± 1.02 73.30± 0.61 0.025 0.009 0.022 0.799
Dmean(Gy) 66.23± 0.93 65.55± 1.08 66.47± 0.91 0.001 0.005 0.333 0.005
V60(%) 96.36± 0.87 96.13± 0.95 97.88± 0.44 0.002 0.445 0.005 0.007
CI 0.793± 0.025 0.811± 0.023 0.813± 0.025 0.002 0.005 0.022 0.575
HI 0.230± 0.040 0.217± 0.044 0.199± 0.038 0.001 0.047 0.005 0.005
Abbreviations: CI = conformity index; HI = homogeneity index; D99% = dose received by 99% of the volume; p1 =Wilcoxon test p value between RA-FFF and RA plans;
p2 =Wilcoxon test p value between RA-FFF and IMRT plans; p3 =Wilcoxon test p value between RA and IMRT plans. Other abbreviations as in Table 1.
delivered the highest mean doses to the parotid glands and
larynx while RA delivered the lowest mean doses.
Table 4 lists the mean gamma score, delivery time and
MUs, grouped by plantype. Patient-specific dose verifi-
cations were performed for 10 plans in three different
techniques. All three techniques showed equally good
gamma scores. Dose computation, as well as dose delivery,
was equally accurate for RA-FFF, RA and IMRT delivery
with gamma analysis performed at 3%/3mm. All the plans
had a GI above 95%. The delivery times for RA-FFF and
Table 3 Comparison of OAR doses among the three techniques
OARs RA-FFF(Gy) RA(Gy) IMRT(Gy) p value p1 p2 p3
Spinal cord D1% 41.22± 2.51 39.58± 2.21 40.00± 1.46 0.061 — — —
Brain stem D1% 55.58± 3.25 53.22± 3.35 52.82± 2.52 0.014 0.013 0.017 0.359
Optic nerve (right) D1% 16.91± 22.14 17.93± 21.52 16.45± 19.50 0.007 0.059 0.959 0.059
Optic nerve (left) D1% 15.26± 18.32 16.55± 17.28 14.15± 15.75 0.061 — — —
Len (right) D1% 5.36± 2.65 5.74± 2.36 5.35± 2.54 0.236 — — —
Len (left) D1% 5.11± 2.08 5.32± 1.83 4.90± 1.95 0.232 — — —
Larynx Dmean 32.55± 2.97 31.83± 2.69 35.40± 1.90 0.001 0.025 0.007 0.005
Oral cavity Dmean 34.12± 2.23 33.31± 1.90 33.52± 1.38 0.025 0.017 0.169 0.646
Parotid (right) Dmean 35.95± 4.32 34.00± 3.87 36.57± 4.15 0.001 0.005 0.445 0.005
Parotid (left) Dmean 34.67± 3.62 33.47± 3.16 35.36± 2.97 < 0.001 0.005 0.059 0.005
Normal tissue Dmean 16.24± 2.10 16.41±2.09 16.20± 2.04 0.150 — — —
Skin Dmean 17.24± 2.31 16.82± 2.27 16.75± 2.32 0.008 0.017 0.007 0.646
Abbreviations: Abbreviations as in Table 2.
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Table 4 Comparison of GI, delivery time andMUs among the three techniques
Parameters RA-FFF RA IMRT p value p1 p2 p3
GI 98.53% ± 1.02% 98.49% ± 1.28% 98.66% ± 1.04% 0.746 — — —
Time(s) 152± 7 153± 7 493± 24 < 0.001 0.539 0.005 0.005
MUs 536± 46 501± 25 1199± 129 < 0.001 0.022 0.005 0.005
Abbreviations: GI = gamma index; MUs = monitor units; Other abbreviations as in Table 2.
RA were 152 ± 7s and 153 ± 7s, respectively, which was
reduced by nearly 70% compared to that of IMRT with
the mean time of 493 ± 24s. The MUs were significantly
different among the three techniques (p< 0.001).
Discussion
Radiotherapy of NPC is a challenging task because of the
complex anatomy, with bones, surrounding OARs and air
cavities all in need of consideraion. Novel radiotherapy
techniques are able to effectively reduce the treatment
side effects, while maintaining good local control. Accord-
ing to a study by White et al. [19] on the radiation doses
in VMAT and IMRT for NPC, VMAT showed superior,
or comparable, dose conformity and target coverage in
the PTVs. VMAT plans also achieved significant improve-
ments in dose reduction to OARs and a significant
reduction in treatment delivery time for VMAT treat-
ment technique was noted. It has also been indicated
that given the similar target dose coverage, VMAT is
able to treat NPC more efficiently with less damage to
OARs [13]. Lee et al. [11] found that dual arc VMAT
produced plans with similar target coverage, as well as
sparing OARs, as compared to 7-field IMRT. VMAT
outperformed IMRT by effectively reducing the delivery
time.
However, these previous studies did not compare the
difference between FFF beams and conventional beams
in VMAT for NPC. FFF beams have several potential
advantages, such as increased dose rate, reduced collima-
tor scatter, reduced head leakage, and reduced out-of-field
doses to the patient. This study was to assess the role
of FFF beams in VMAT with a focus on advanced NPC.
Based on dosimetric evaluation in this study, it can be
found that all the treatment plans could meet the plan-
ning objectives, and the RapidArc technique can treat
patients with advanced NPC effectively, with good target
coverage and sparing of critical structures, results sim-
ilar to those found by others [13,19]. RA-FFF showed
poorer conformity and heterogeneity compared to other
techniques. This suggests that FFF beams might be appli-
cable for treatment of large targets in a complex anatomic
situation, with adequate doses to the targets and RA
was more likely to give lower dose to most OARs and
achieve better conformity for the PTVs. We have also
focused on dosimetric verification in this study. The
evaluation of computed dose on Eclipse and delivered
dose at TrueBeam measured by the Delta4 indicated
an excellent agreement for all the techniques. Gamma
analysis demonstrated that all the plans were verified,
with > 95% of the measured points meeting the 3%/3mm
criterion.
Our results are in contrast to those observed in other
studies involving FFF beams for large and complex tar-
gets. Nicolini et al. [6] and Subramaniam et al. [7] reported
that RapidArc with FFF beams provides minor improve-
ments in plan quality, suggesting their applicability for
large and complex targets. However, these studies just
included one target. The number of OARs (≤ 5) was
less than that of this study. In this study, the target vol-
umes of three different dose levels, PTV70, PTV66 and
PTV60 were delivered in a simultaneous boost plan. The
lengths of the targets are >20cm and the targets are
surrounded by many critical neural tissues and sensitive
structures such as optic nerves, brain stem, oral cavity, and
parotid glands. The RA superiority over RA-FFF is possi-
bly due to the use of rather large field sizes and complex
target volumes.
The VMAT advantage in shortening the treatment
time compared to IMRT plans is well known. In this
study, the average delivery time for RA-FFF and RA was
152± 7s and 153± 7s, respectively, which was nearly
70% shorter than that of IMRT. Furthermore, the dose
rate for the FFF beams can be substantially higher than
the conventional beams (1400 MU/min vs 600MU/min).
However, no significant difference in the delivery time
was found between RA-FFF and RA. Although high dose
rate (more than 1000 MU/min) was observed in RA-FFF,
it did not lead to improvements in the delivery time. This
is because in our cases the delivery time is largely limited
by the gantry rotation speed and leaf speed, not the dose
rate. In the hypofractionated treatment for liver tumours,
Mancosu et al. [20] found that RapidArc with FFF beams
resulted to be feasible with short beam on time.
In this study RA-FFF tended to show a lower mean
dose to normal tissue compared to RA. It appears possi-
ble to predict a reduction of out-of-field dose when FFF
beams are used. This is mainly related to reduced head
scattering and residual electron contamination. However,
the MUs in the RA-FFF plans were always greater than
in the RA plans. The reason is that FFF beam intensity
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decreases with the off-axis distance, which can be clearly
observed in larger field (≥ 10 × 10cm2) open beam dose
profiles. As a result, off-axis distance-dependent modula-
tion is needed for delivering uniform doses to large target
volumes, possibly leading to greater MUs. This will lead,
at least partially, to cancellation of the potential advan-
tages for FFF beams such as reduced head scatter and
out-of-field doses.
The spectrum of a 6 MV FFF beam is typically softer
because the flattening filter acts as a beam hardener. The
different spectrum of unflattened beams is reflected in the
depth dose distribution. Vassiliev et al. [21] found that the
depth dose distribution of unflattened 6 MV beams was
similar to that of conventional 4–5 MV beams. Due to the
softer spectrum of FFF beams, a slightly higher dose to
the skin can be expected. A mitigating factor to this is that
the scattered radiation and electron contamination from
the flattening filter are eliminated. Among the three tech-
niques RA-FFF provided for the highest mean dose to the
skin. This could be avoided by using higher energies, e.g.,
8 MV instead of 6 MV [9].
The collimator angles were fixed at 0° for IMRT plan-
ning in our study. A published study by Deng et al. [22]
demonstrated that the tongue-and-groove effect was clin-
ically insignificant for multiple-field IMRT because of the
smearing effect of individual fields and the collimator
angle was set to 180° which played a fundamental role
in smearing effect of tongue-and-groove. However, some
degree of collimator rotation is usually carried out in
VMAT to minimize the cumulative effects of the tongue-
and-groove effect and interleaf transmission [23]. In our
study a 30° collimator angle in RapidArc was chosen.
Mans et al. [24] indicated that a better plan quality could
be achieved using a collimator rotation between 20° and
30°. Clivio et al. [17], Vanetti et al. [25] and Cozzi et al.
[26] also used a 30–45° collimator rotation in the VMAT
planning.
Conclusions
This study demonstrates that, in the treatment planning
of advanced NPC, RapidArc technique can treat patients
with advanced NPC effectively, with good target coverage
and sparing of critical structures, and RA gave superior,
or similar sparing of OARs than other techniques. All the
treatment plans could meet the planning objectives. The
dose measurements also showed good agreement with
computed doses. Although RA-FFF shows the potential
for treatment of advanced NPC patients with adequate
target coverage and sparing of OARs, RA has a greater
dosimetric superiority than RA-FFF, and further studies
are still required to evaluate their clinical outcomes.
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